Valeant Pharmaceuticals Intl Inc  

(Public, NYSE:VRX)   Watch this stock  
Find more results for VRX
29.32
+2.38 (8.83%)
Real-time:   1:27PM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 27.84 - 29.41
52 week 23.55 - 263.81
Open 28.19
Vol / Avg. 23.17M/31.30M
Mkt cap 9.92B
P/E     -
Div/yield     -
EPS -0.84
Shares 341.19M
Beta 0.20
Inst. own 58%
Jun 8, 2016
Q1 2016 Valeant Pharmaceuticals International Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 25, 2016
Valeant Pharmaceuticals International Inc Annual Shareholders Meeting (Estimated)
May 23, 2016
Valeant Pharmaceuticals International Inc at UBS Global Healthcare Conference
Mar 15, 2016
Q4 2015 Valeant Pharmaceuticals International Inc Earnings Release
Mar 15, 2016
Orexigen Therapeutics Inc to Discuss Acquisition of U.S. Rights to Contrave and the Central and Eastern European Partnership with Valeant Pharmaceuticals International, Inc. Conference Call - Webcast
Mar 15, 2016
Q4 2015 Valeant Pharmaceuticals International Inc Earnings Call Unaudited
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -13.24% -2.75%
Operating margin 7.12% 14.43%
EBITD margin - 45.71%
Return on average assets -2.98% -0.76%
Return on average equity -23.69% -5.21%
Employees 22,000 -
CDP Score - -

Address

2150 Saint-Elzear Blvd W
LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)
+1-514-7446272 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company's developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Company's Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.

Officers and directors

Joseph C. Papa Chairman of the Board, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
Robert L. Rosiello Chief Financial Officer, Executive Vice President
Age: 57
Bio & Compensation  - Reuters
Pavel Mirovsky President and General Manager, Europe
Age: 64
Bio & Compensation  - Reuters
Robert Roswell Chai-Onn Executive Vice President, General Counsel and Chief Legal Officer, Head of Corporate and Business Development, Director
Age: 44
Bio & Compensation  - Reuters
Ari S. Kellen Executive Vice President, Company Group Chairman
Age: 51
Bio & Compensation  - Reuters
Laizer D. Kornwasser Executive Vice President, Company Group Chairman
Age: 44
Bio & Compensation  - Reuters
Brian M. Stolz Executive Vice President - Administration, Chief Human Capital Officer
Age: 40
Bio & Compensation  - Reuters
William A. Ackman Director
Age: 49
Bio & Compensation  - Reuters
Fredric N. Eshelman Independent Director
Bio & Compensation  - Reuters
Ronald Harold Farmer Independent Director
Age: 64
Bio & Compensation  - Reuters